Blurbs

Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Outlook Therapeutics (OTLK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERUResearch Report), Outlook Therapeutics (OTLKResearch Report) and Inventiva (IVAResearch Report) with bullish sentiments.

Veru (VERU)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru, with a price target of $21.00. The company’s shares closed last Monday at $6.07, close to its 52-week low of $4.37.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.8% and a 36.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $21.00 average price target, implying a 231.8% upside from current levels. In a report issued on February 9, Oppenheimer also maintained a Buy rating on the stock with a $25.00 price target.

See today’s best-performing stocks on TipRanks >>

Outlook Therapeutics (OTLK)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Outlook Therapeutics today and set a price target of $6.00. The company’s shares closed last Monday at $1.33, close to its 52-week low of $1.19.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

Outlook Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

Inventiva (IVA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Inventiva today and set a price target of $42.00. The company’s shares closed last Monday at $12.54.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.0% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inventiva.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VERU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos